Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients
Transplant International · 27.11.2025 · 38
DOI: 10.3389/ti.2025.15425 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Transplant International, online erschienen am 27.11.2025. Verfasst von Tomas Lorant und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Sciences, Section of Transplant Surgery, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Kidney Transplantation, Desensitization, Immunologic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In four phase 2 clinical trials, patients underwent imlifidase-enabled kidney transplantation, converting a positive crossmatch (+XM) to negative. Here, we present data from 39 patients enrolled in the 5-year follow-up extension trial. Patient survival, graft survival, renal function, delayed graft function (DGF) antibody mediated rejection (AMR) frequency, safety and presence of donor specific antibodies (DSAs) are presented. Data from the long-term follow-up trial (17-HMedIdeS-14); NCT 03611621) with planned visits at 1, 2, 3, and 5 years after imlifidase were combined with up to 6-month phase 2 data from 4 pivotal trials (13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS-04, 15-HMedIdeS-06). Five-year patient survival was 90% with 3 deaths occurring between 6 months and 1 year, with no deaths occurring subsequently. Death-censored graft survival was 82% (with 3 early graft losses and 3 graft losses between 2 and 5 years). Mean eGFR at 5 years was 50.1 (MDRD), 55.8 (CKD-EPI, 2021) and 52.5 (KRS, 2023) mL/min/1.73 m 2 (N = 24 patients) among functioning grafts. DSA rebounded with levels progressively decreasing over time and no increase in DSA seen between 3 and 5 years. No AMR occurred between 3 and 5 years. Furthermore, no additional safety signals assessed as related to imlifidase were reported in this cohort. At 5 years, highly-HLA sensitized patients who underwent imlifidase desensitization prior to transplantation demonstrated excellent patient and graft survival, despite their high-risk immunological profile. Imlifidase offers a viable and effective treatment option for highly sensitized patients to achieve life-saving transplantation and continued optimism is warranted. Clinical Trial ClinicalTrials.gov (NCT02790437), EudraCT Number: 2016-002064-13.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Sciences, Section of Transplant Surgery, Uppsala University, Uppsala, Sweden.
- Department of Surgery, NYU Langone Transplant Institute, New York, NY, United States.
- Northwell Transplant Institute, Manhassett, NY, United States.
- Nephrology and Transplantation Unit, Hôpital Necker and Université Paris Cité, Paris, France.
- Department of Transplantation Surgery, Karolinska Institutet, Stockholm, Sweden.
- Cedars-Sinai Medical Center, Comprehensive Transplant Center, Los Angeles, CA, United States.
Zitieren
APA
Lorant, T., Lonze, B. E., Montgomery, R. A., Desai, N. M., Legendre, C., Lundgren, T., von Zur-Mühlen, B., Vo, A. A., Sjöholm, K., Runström, A., Tollemar, J., & Jordan, S. C. (2025). Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients. Transplant International, 38. https://doi.org/10.3389/ti.2025.15425
Vancouver
Lorant T, Lonze BE, Montgomery RA, Desai NM, Legendre C, Lundgren T, et al. Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients. Transplant International. 2025;38. doi:10.3389/ti.2025.15425
BibTeX
@article{Lorant2025,
author = {Lorant, Tomas and Lonze, Bonnie E and Montgomery, Robert A and Desai, Niraj M and Legendre, Christophe and Lundgren, Torbjörn and von Zur-Mühlen, Bengt and Vo, Ashley A and Sjöholm, Kristoffer and Runström, Anna and Tollemar, Jan and Jordan, Stanley C},
title = {Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients},
journal = {Transplant International},
year = {2025},
volume = {38},
doi = {10.3389/ti.2025.15425}
}
EUVIMED